ProQR Therapeutics (PRQR) Operating Leases (2017 - 2026)
ProQR Therapeutics (PRQR) posted Operating Leases of $10.6 million for Q1 2026, down 4.44% sequentially from $11.1 million in Q4 2025, and down 5.98% YoY from $11.3 million in Q1 2025.
ProQR Therapeutics (PRQR) Operating Leases (2017 - 2026) Analysis & Trends
ProQR Therapeutics has reported Operating Leases for 10 years, with the latest figure at $10.6 million in Q1 2026.
- Quarterly Operating Leases fell 5.98% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.6 million (down 5.98% YoY) and the FY2025 annual result came in at $11.1 million, down 6.03% from the prior year.
- Operating Leases slipped to $10.6 million in Q1 2026 per PRQR's latest filing, from $11.1 million in the prior quarter.
- Over five years, Operating Leases peaked at $16.1 million in Q1 2022 and troughed at $10.6 million in Q1 2026.
- A 5-year average of $13.5 million and a median of $14.1 million in 2022 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2025: Operating Leases soared 86630.68% in 2022, then fell 22.25% in 2025.
- Over 5 years, Operating Leases stood at $14.1 million in 2022, then gained by 5.57% to $14.9 million in 2023, then retreated by 20.51% to $11.8 million in 2024, then slipped by 6.03% to $11.1 million in 2025, then retreated by 4.44% to $10.6 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $10.6 million, $11.1 million, and $11.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.62 Mn |
| Dec 31, 2025 | 11.11 Mn |
| Sep 30, 2025 | 11.71 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Mar 31, 2025 | 11.30 Mn |
| Dec 31, 2024 | 11.83 Mn |
| Sep 30, 2024 | 12.63 Mn |
| Jun 30, 2024 | 14.08 Mn |
| Mar 31, 2024 | 14.53 Mn |
| Dec 31, 2023 | 14.88 Mn |
| Sep 30, 2023 | 15.85 Mn |
| Jun 30, 2023 | 14.92 Mn |
| Mar 31, 2023 | 14.42 Mn |
| Dec 31, 2022 | 14.09 Mn |
| Sep 30, 2022 | 14.31 Mn |
| Jun 30, 2022 | 15.54 Mn |
| Mar 31, 2022 | 16.14 Mn |
| Dec 31, 2021 | 16.87 Mn |
| Sep 30, 2021 | 17.82 Mn |
| Jun 30, 2021 | 18.63 Mn |